Category: Hypersomnias

Hypersomnias

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

New data from a long-term extension study demonstrates sustained improvements in wakefulness, cognition, and fatigue for adults with narcolepsy type 1 and type 2.

Hypersomnias

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.

Hypersomnias

Will Orexin Drugs Raise the Bar for Clinical Diagnosis of Hypersomnolence?

As mechanism-based orexin agonists get close to market, sleep physicians may feel compelled to reduce ambiguity between narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia diagnoses.

Narcolepsy

Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

The acquisition centers on Centessa’s pipeline of orexin receptor 2 agonists, including lead candidate cleminorexton, targeted for narcolepsy and idiopathic hypersomnia.

Idiopathic Hypersomnia

FDA Grants Orphan Drug Designation to IH Drug Contender

A phase 3 trial is underway to evaluate the drug's efficacy and safety in adults with IH, with enrollment expected to complete by the end of 2025.

Insufficient Sleep Syndrome

Sleep Disorders and Lack of Sleep Plague Active US Military Personnel

A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.

When Seizures Strike Sleep

Kleine-Levin Syndrome

Kleine-Levin Syndrome Foundation Taps First Executive Director

An experienced non-profit leader and author is appointed to the first-ever professional staff role for the foundation.